{"id":172083,"name":"MCKESSON CORPATION AND ITS AFFILIATE US ONCOLOGY (FORMERLY US ONCOLOGY)","slug":"mckesson-corpation-and-its-affiliate-us-oncology-formerly-us-oncology","state":"TX","description":null,"totalSpending":1380000,"filings":23,"yearlySpending":[{"year":2018,"income":240000},{"year":2019,"income":120000},{"year":2020,"income":180000},{"year":2021,"income":240000},{"year":2022,"income":180000},{"year":2024,"income":180000},{"year":2025,"income":240000}],"firms":["STANTON PARK GROUP"],"lobbyists":["JAMES DERDERIAN","ERIN STRAWN","VALERIE HENRY","EMILY SHETTY","SARAH HAMLETT","JOSEPH RACHINSKY","ANDREA BERGMAN","BRYAN WELLS","AISLING MCDONOUGH"],"issues":["MMM","VET","HCR"],"sampleDescriptions":["Medicare, oncology, radiation and imaging reimbursement issues\nMedicare physician payments\nprompt pay discount\nOncology payment disparities in Medicare and protecting access to community based cancer care\nReimbursement of cancer care services by the Veterans Administration\nIssues related to physician reimbursement for Part B drugs\nSupport for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635) \n340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices","Issues related to reimbursement from the Department of Veterans Affairs.","reimbursement for cancer care services","Medicare, oncology, radiation and imaging reimbursement issues\nMedicare physician payments\nprompt pay discount\nOncology payment disparities in Medicare and protecting access to community based cancer care\nIssues related to physician reimbursement for Part B drugs\n340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices\nS. 1895, the Lower Health Care Costs Act. \nH.R. 2296, the FAIR Drug Pricing Act of 2019.\nH.R. 3630, the No Surprises Act\"\nThe Lower Health Care Costs Act","Medicare, oncology, radiation and imaging reimbursement issues\nMedicare physician payments\nprompt pay discount\nOncology payment disparities in Medicare and protecting access to community based cancer care\nIssues related to physician reimbursement for Part B drugs\n340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices\nS. 1895, the Lower Health Care Costs Act. \nH.R. 2296, the FAIR Drug Pricing Act of 2019.\nH.R. 3630, the No Surprises Act\"\nThe Lower Health Care Costs Act\nCOVID and the impact on cancer care","Medicare, oncology, radiation and imaging reimbursement issues\nMedicare physician payments\nprompt pay discount\nOncology payment disparities in Medicare and protecting access to community based cancer care\nIssues related to physician reimbursement for Part B drugs\n340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices\nS. 1895, the Lower Health Care Costs Act. \nH.R. 2296, the FAIR Drug Pricing Act of 2019.\nH.R. 3630, the No Surprises Act\"\nThe Lower Health Care Costs Act\nCOVID and the impact on cancer care\ndrug pricing regulations","Medicare, oncology, radiation and imaging reimbursement issues; medicare physician payments; Oncology payment disparities in Medicare.; Health information technology; application of the sequester to cancer drug reimbursement; prompt pay discount; safety and security of the prescription drug supply chain.","H.R.2484, Seniors Access to Critical Medications Act of 2025"],"years":[2018,2019,2020,2021,2022,2024,2025]}